ClinicalTrials.gg
Not yet recruitingNCT06701604Updated Nov 22, 2024

Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

An interventional study of Single Strain Probiotic + Milk Protein and Placebo + Milk Protein in Amino Acid Absorption and Probiotic, sponsored by The Archer-Daniels-Midland Company. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by The Archer-Daniels-Midland Company · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of this study is to examine the rate and concentration of amino acid absorption after a three-week pattern of milk protein supplementation with and without the addition of a single strain probiotic.

Read the detailed description

The study will be conducted using a randomized, double-blind, crossover study design. Thirty healthy men and women between 18 - 35 years of age will be recruited to participate in this study. Two supplementation protocols that each span three weeks will be completed and separated with a washout period of three weeks. Participants will be assigned in a randomized, double-blind, crossover fashion to ingest a single daily 25-gram dose of a powder milk protein and placebo or a single daily 25-gram dose of a powder milk protein plus a single strain probiotic. Upon arrival for each study visit, participants will have their resting heart rate, blood pressure, body mass, height, and body composition measured. On the day of experimental testing, subjects will arrive to the laboratory in a fasted state. Subjects will rest semi-supine for multiple blood sampling. Following baseline sampling, participants will ingest their respective supplement plus a standard bolus of milk protein (powder form, mixed with 12 fl oz of cold water). Thereafter, blood samples will be taken at 30, 60, 90, 120, 180, and 240 minutes post-ingestion. Study participants will be provided an additional three-week supply of the alternative treatment to begin after observing a three-week washout. After three weeks of supplementation, study participants will return to the laboratory for their remaining testing visit.

02

Conditions studied

  • Amino Acid Absorption
  • Probiotic
03

In context

Lead sponsor

The Archer-Daniels-Midland Company is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants will be male or female between the ages of 18-35 years;
  • Participants have not been consuming any nutritional supplements for the preceding 6-week period;
  • Participants have not been consuming any ergogenic aids for the preceding 6-week period;
  • Participant has provided written and dated to participate in the study;
  • Participant is willing and able to comply with the protocol;
  • Participant is apparently healthy and free from disease, as determined by a health history questionnaire;

Exclusion criteria

Exclusion Criteria:

  • Participant is allergic to any ingredient in the nutritional supplement or placebo;
  • Participant is not pregnant or trying to become pregnant, nor breast feeding;
  • Participant reports any unusual adverse events associated with this study that in consultation with the study investigators or their doctor recommends removal from the study;
  • Participant currently ingests nicotine or has quit within the last 6 months;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Milk Protein + Probiotic

    Arm receiving investigational product (probiotic) in the form of a capsule with a dose of 1B Colony Forming Unit (CFU) per day + a 25-gram dose of milk protein concentrate given daily for 3 weeks

    Dietary Supplement: Single Strain Probiotic + Milk Protein

  • Placebo comparator
    Milk Protein + Placebo

    Arm receiving placebo matching investigational product + a 25-gram dose of milk protein concentrate given daily for 3 weeks

    Dietary Supplement: Placebo + Milk Protein

Interventions

  • Dietary supplementSingle Strain Probiotic + Milk Protein

    • Both conditions matched flavor, color, and serving size

  • Dietary supplementPlacebo + Milk Protein

    • Both conditions matched flavor, color, and serving size

06

What researchers measure

Primary outcomes

  1. Rate of amino acid absorption

    To determine if the addition of a probiotic to milk protein ingestion changes the rate (in minutes) to which amino acids are absorbed into our bloodstream.

    Time frame: Day 0, Day 22, Day 65

  2. Concentration of amino acid absorption

    To determine if the addition of a probiotic to milk protein ingestion changes the extent (concentration in millimoles/Liter) to which amino acids are absorbed into our bloodstream.

    Time frame: Day 0, Day 22, Day 65

Secondary outcomes

  1. Comprehensive metabolic panel

    Comprehensive metabolic panel will be assessed pre vs. post supplementation across the two treatment groups for blood safety data. • All measures are assessed by blood or serum assay analysis

    Time frame: Day 0, Day 22, Day 65

  2. Blood CBC panel

    Blood CBC panel will be assessed pre vs. post supplementation across the two treatment groups for blood safety data. • All measures are assessed by blood or serum assay analysis

    Time frame: Day 0, Day 22, Day 65

07

Study locations

1 site
  • The University of Mary Hardin-Baylor
    Belton, Texas 76513, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Jan 2026, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 22, 2024
StartEst.
Dec 2, 2024
Primary completionEst.
Jan 15, 2026
CompletionEst.
Jan 15, 2026
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06701604
Lead sponsor
The Archer-Daniels-Midland Company
Collaborators
University of Mary Hardin-Baylor
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Dec 2, 2024 (estimated)
Primary completion
Jan 15, 2026 (estimated)
Completion
Jan 15, 2026 (estimated)
Last update
Nov 22, 2024

Study contacts

Lem Taylor, PhD
Contact
ltaylor@umhb.edu
254-295-4895

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion